Cargando…

Abi1 gene silencing by short hairpin RNA impairs Bcr-Abl-induced cell adhesion and migration in vitro and leukemogenesis in vivo

Abl interactor (Abi) 1 was first identified as the downstream target of Abl tyrosine kinases and was found to be dysregulated in leukemic cells expressing oncogenic Bcr-Abl and v-Abl. Although the accumulating evidence supports a role of Abi1 in actin cytoskeleton remodeling and growth factor/recept...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Weidong, Sun, Xiaolin, Clough, Nancy, Cobos, Everardo, Tao, Yunxia, Dai, Zonghan
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2008
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527646/ https://www.ncbi.nlm.nih.gov/pubmed/18453543 http://dx.doi.org/10.1093/carcin/bgn098

Ejemplares similares

CRISPR/CAS9-mediated knockout of Abi1 inhibits p185(Bcr-Abl)-induced leukemogenesis and signal transduction to ERK and PI3K/Akt pathways
por: Faulkner, James, et al.
Publicado: (2020)

Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis
por: Baum, Karina J, et al.
Publicado: (2008)

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis
por: Grebien, Florian, et al.
Publicado: (2011)

Autophagy is Essential to Suppress Cell Stress and to Allow BCR-Abl-Mediated Leukemogenesis
por: Altman, Brian J., et al.
Publicado: (2010)

PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis
por: Berger, A, et al.
Publicado: (2014)

BCR-ABL triggers a glucose-dependent survival program during leukemogenesis through the suppression of TXNIP
por: Feng, Lin, et al.
Publicado: (2023)

Signal Transducer and Activator of Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for Leukemogenesis
por: Nieborowska-Skorska, Malgorzata, et al.
Publicado: (1999)

Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis
por: Gerboth, S, et al.
Publicado: (2018)

The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis
por: Mian, Afsar A., et al.
Publicado: (2019)

Monoubiquitinated Fanconi Anemia D2 (FANCD2-Ub) Is Required for BCR-ABL1 Kinase -Induced Leukemogenesis
por: Koptyra, Mateusz, et al.
Publicado: (2011)

c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells
por: Waldron, Todd, et al.
Publicado: (2011)

BCR‐ABL enhances the prolyl isomerase activity of Pin 1 by interacting with DAPK1 in ph(+) ALL
por: Cao, Wen‐bin, et al.
Publicado: (2018)

Low Expression of miR-196b Enhances the Expression of BCR-ABL1 and HOXA9 Oncogenes in Chronic Myeloid Leukemogenesis
por: Liu, Yue, et al.
Publicado: (2013)

Creation of Philadelphia chromosome by CRISPR/Cas9-mediated double cleavages on BCR and ABL1 genes as a model for initial event in leukemogenesis
por: Tamai, Minori, et al.
Publicado: (2022)

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
por: Kauer, Joseph, et al.
Publicado: (2022)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

P62(dok), a Negative Regulator of Ras and Mitogen-Activated Protein Kinase (Mapk) Activity, Opposes Leukemogenesis by P210(bcr-abl)
por: Di Cristofano, Antonio, et al.
Publicado: (2001)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
por: Etienne, Gabriel, et al.
Publicado: (2019)

Using healthcare claims data to analyze the prevalence of BCR‐ABL‐positive chronic myeloid leukemia in France: A nationwide population‐based study
por: Foulon, Stéphanie, et al.
Publicado: (2019)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

The Abl/Abi signaling links WAVE regulatory complex to Cbl E3 ubiquitin ligase and is essential for breast cancer cell metastasis
por: Jiang, Peixin, et al.
Publicado: (2022)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months
por: Casado, Luis-Felipe, et al.
Publicado: (2015)

Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR‐ABL inhibitor use by using an adverse drug event reporting database
por: Okada, Naoto, et al.
Publicado: (2018)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

An In-House Method for Molecular Monitoring of BCR-ABL
por: Sercan, Hakkı Ogün, et al.
Publicado: (2012)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

PKCβ Facilitates Leukemogenesis in Chronic Lymphocytic Leukaemia by Promoting Constitutive BCR-Mediated Signalling
por: Hay, Jodie, et al.
Publicado: (2022)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR‐ABL1‐like acute lymphoblastic leukemia
por: Lee, Jae Wook, et al.
Publicado: (2020)

HBO1-MLL interaction promotes AF4/ENL/P-TEFb-mediated leukemogenesis
por: Takahashi, Satoshi, et al.
Publicado: (2021)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels
por: Klamová, Hana, et al.
Publicado: (2013)

Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia
por: Vinhas, Raquel, et al.
Publicado: (2017)

HOXA9 promotes MYC-mediated leukemogenesis by maintaining gene expression for multiple anti-apoptotic pathways
por: Miyamoto, Ryo, et al.
Publicado: (2021)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_svrvel47g8bbrdvcnka7s74iiq